RLAY SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 4, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 5, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 26, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates

Nov 4, 2026

8-K

Relay Therapeutics Amends Common Stock Sales Agreement to Increase Offering Capacity

Aug 6, 2026

8-K

Relay Therapeutics, Inc. Announces Results of 2026 Annual Meeting and Increase in Authorized Shares

Jun 9, 2026

8-K

Relay Therapeutics, Inc. Announces Pricing and Full Exercise of Underwriter Option for Common Stock Offering

May 21, 2026

8-K

Relay Therapeutics Announces Positive Initial Clinical Data for Zovegalisib in PIK3CA-Driven Vascular Anomalies

May 19, 2026

8-K

Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates

May 5, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

August 2026 ATM | Offering amount: $212,978,049 | Bank: TD Securities (USA) LLC

Aug 6, 2026

424B5

REGISTERED OFFERING

May 21, 2026

424B5

PENDING FIXED PRICE OFFERING | Offering amount: $175,000,000 | Bank: Jefferies, TD Cowen, Goldman Sachs & Co. LLC, Guggenheim Securities, Raymond James

May 19, 2026

424B5

SHELF OFFERING | Shares amount: 28,571,429 | Share price: $7.00 | Offering amount: $200,000,003.00 | Bank: Goldman Sachs & Co. LLC, TD Cowen, Stifel, BofA Securities, Raymond James

Sep 11, 2024

424B5

.00 | Offering amount: $200,000,000.00 | Bank: Goldman Sachs & Co. LLC, TD Cowen, Stifel, BofA Securities, Raymond James

Sep 9, 2024

424B7

2,500,000 Shares

Jan 10, 2024

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 26, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 26, 2025

S-3ASR

Up to $250,000,000 Common Stock PROSPECTUS TD Cowen August 6, 2024

Aug 6, 2024

S-8

Registration

Feb 22, 2024

Form D - Notice of Exempt Offering of Securities - Item 06b

Jan 10, 2024

S-8

Registration

Feb 23, 2023

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

Rahmer Peter (Reporting)

Oct 30, 2026

Bergstrom Donald A (Reporting)

Oct 30, 2026

Catinazzo Thomas (Reporting)

Oct 30, 2026

Patel Sanjiv (Reporting)

Oct 8, 2026

Catinazzo Thomas (Reporting)

Oct 8, 2026

144

Form 144 - Report of proposed sale of securities

Oct 7, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

May 7, 2021

CORRESP

Form CORRESP - Correspondence

May 4, 2021

LETTER

Form UPLOAD - SEC-generated letter

May 3, 2021

EFFECT

Form EFFECT - Notice of Effectiveness

Jul 16, 2020

CORRESP

Form CORRESP - Correspondence

Jul 14, 2020

LETTER

Form UPLOAD - SEC-generated letter

Jul 14, 2020

Relay Therapeutics, Inc. RLAY · SEC Filings